Daewoong Pharmaceutical said that it received approval from the U.S. Food and Drug Administration for Nabota, its botulinum toxin (BTX) product, in treating forehead wrinkles, on Feb. 1
The FDA’s go-ahead has made Nabota the first Korean BTX product to enter the U.S., which is the world's largest botulinum toxin market, the company said on Thursday. Evolus, Daewoong’s U.S. partner, will supply products in the U.S.
“We are delighted to provide U.S. patients and physicians with a competitive solution to improve wrinkles,” Daewoong Pharmaceutical CEO Jeon Seng-ho said. “As Nabota's superior quality, safety and efficacy have been proven, we are confident that we will be successful in North American markets such as the US and Canada.”
Nabota's approval by the FDA is an exciting opportunity for Daewoong to become a global pharmaceutical company, Jeon added.
Evolus CEO David Moatazedi also said, “We have become the first company to introduce a new product to the U.S. cosmetic neurotoxin market in about 10 years. Based on Evolus' expert know-how and strategy, we plan to launch Jeuveau in the U.S successfully.”